On April 19, Moscow hosted the largest conference in the field of ophthalmology “Ophthalmology 360°. Health care, marketing, digitalization, law", which brought together leading industry experts: practicing ophthalmologists, representatives of regulatory bodies in the field of health care, specialists in the field of medical law and marketing.

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2024 the firm is ranked among the TOP leading legal advisors in Russia. 

On April 11, 2024, in Moscow, the annual Pravo.ru conference "Pharmaceuticals – 2024: Legal Issues" will take place. Lidings lawyers traditionally take an active part in the event’s program.

As a strategic partner of the conference, we have endeavored to make the program as comprehensive and useful as possible. Together with experts from the pharmaceutical industry and legal experts, we will discuss current issues in industry regulation, legislative changes, market access, government procurement, and distribution. We will also touch upon marketing and promotion issues, as well as discuss strategies for protecting intellectual property.

Lidings is pleased to announce Natalya Thotahewage, a recognized expert in pharmaceuticals and healthcare, joining the firm as counsel and the appointment of Elizaveta Fursova, Head of the Lidings' Employment practice, as counsel.

On 7 December 2023 the results of the annual Pravo-300 law firms’ ranking were announced at an awarding ceremony at The Carlton Hotel in Moscow. This year Lidings expertise is highly praised in 15 key practice areas.

The new review of the most notable patents disputes in Life Sciences in EAEU.

• pdf, 4.45 Mb

By its Ruling of 25.09.2023 in case No. A40-185112/2022, the Ninth Commercial Court of Appeal ordered the pharmaceutical company Vertex, the right holder of a series of patents for the drug Trikafta (INN: Ivacaftor+Tezacaftor+Elexacaftor, Ivacaftor), to grant a simple (non-exclusive) license to the Russian pharmaceutical company MIK under Article 1362(1) of the Russian Civil Code (insufficient use of patents).

Lidings’ IP team has successfully secured recognition of the Doppelherz brand as a well-known trademark specifically for dietary supplements, setting a valuable precedent. The interests of the client, the German pharmaceutical company Queisser Pharma, which owns the brand, were represented by Boris Malakhov, Partner, and Vladislav Ryabov, Senior Associate.